Awaiting development: Guidance and quality standards

Showing 71 to 80 of 359

Guidance and quality standards awaiting development
Title	Type
Deucravacitinib for treating systemic lupus erythematosus [TSID12405]	Technology appraisal guidance
Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery [ID1154]	Technology appraisal guidance
Divarasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer	Technology appraisal guidance
Donanemab for reducing the risk of mild cognitive impairment in preclinical Alzheimer's disease [ID6675]	Technology appraisal guidance
Doravirine-islatravir for previously untreated HIV-1 infection	Technology appraisal guidance
Doravirine–islatravir for treating HIV-1 in people with virological suppression on antiretroviral therapy	Technology appraisal guidance
Doravirine–islatravir for treating HIV-1 in people with virological suppression on bictegravir, emtricitabine and tenofovir alafenamide combination treatment	Technology appraisal guidance
Dorocubicel for treating haematological cancer when a suitable donor is unavailable for an allogeneic haematopoietic stem cell transplant [ID6521]	Technology appraisal guidance
Dostarlimab for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency when systemic treatment is suitable [ID6660]	Technology appraisal guidance
Dostarlimab for untreated locally advanced rectal cancer with high microsatellite instability or mismatch repair deficiency [ID6747]	Technology appraisal guidance